Dr. Douglas Scharre, director of the Division of Cognitive Neurology and heads the Memory Disorders Research Center at Ohio State's Wexner Medical Center, and colleagues announced the development and successful testing of the first test for Alzheimer’s disease that can be used anywhere in the Jan. 13, 2014, edition of The Journal of Neuropsychiatry and Clinical Neurosciences.
The new test called the Self-Administered Gerocognitive Examination (SAGE test) was tested on 1,047 individuals aged 50 and over from a wide variety of community locations and events, including senior centers, health fairs, educational talks to lay public, independent and assisted-living facilities, and free memory screens through newspaper advertisement. The test was found to be as accurate at determining loss of mental capacity, the progress of dementia, and the development of Alzheimer’s disease as more complicated mental and chemical tests.
The SAGE results were compared to standard clinical analytical test for dementia and Alzheimer’s disease and found to be 80 percent reliable in determining the presence of dementia or Alzheimer’s and 100 percent reliable in finding no dementia or Alzheimer’s disease.
The simple paper test can be completed in 15 minutes. The results can be accessed by a physician and used to intercept the development of dementia or Alzheimer’s disease earlier than standard testing.
An added advantage to the SAGE test is a minimal cost for a high level of accurate prediction.